Cargando…
An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer
This randomized, open‐label, active‐controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long‐acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficac...
Autores principales: | Vacirca, Jeffrey L., Chan, Arlene, Mezei, Klára, Adoo, Clarence S., Pápai, Zsuzsanna, McGregor, Kimberly, Okera, Meena, Horváth, Zsolt, Landherr, László, Hanslik, Jerzy, Hager, Steven J., Ibrahim, Emad N., Rostom, Makharadze, Bhat, Gajanan, Choi, Mi Rim, Reddy, Guru, Tedesco, Karen L., Agajanian, Richy, Láng, István, Schwartzberg, Lee S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943466/ https://www.ncbi.nlm.nih.gov/pubmed/29573207 http://dx.doi.org/10.1002/cam4.1388 |
Ejemplares similares
-
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
por: Schnadig, Ian D, et al.
Publicado: (2017) -
Eflapegrastim, a Long‐Acting Granulocyte‐Colony Stimulating Factor for the Management of Chemotherapy‐Induced Neutropenia: Results of a Phase III Trial
por: Schwartzberg, Lee S., et al.
Publicado: (2020) -
Association of a Lay Health Worker Intervention With Symptom Burden, Survival, Health Care Use, and Total Costs Among Medicare Enrollees With Cancer
por: Patel, Manali I., et al.
Publicado: (2020) -
A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
por: Cobb, Patrick Wayne, et al.
Publicado: (2020) -
Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience
por: Boér, Katalin, et al.
Publicado: (2021)